Pozen inks $75M U.S. royalty deal for Treximet with Canadian pension fund
Pozen (NASDAQ:POZN) has sold the U.S. royalty rights for migraine drug Treximet to Canada’s national pension fund, CPPIB Credit Investments in a $75 million deal. The terms of the deal give the Chapel Hill, North Carolina pharmaceutical company a 20 percent interest in any royalties received by the pension fund starting April 1, 2018, according to […]